We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Register for real-time alerts, custom portfolio, and market movers
| Share Name | Share Symbol | Market | Type |
|---|---|---|---|
| Day One Biopharmaceuticals Inc | NASDAQ:DAWN | NASDAQ | Common Stock |
| Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
|---|---|---|---|---|---|---|---|---|---|---|
| 0.15 | 0.94% | 16.03 | 13.75 | 21.50 | 16.35 | 15.79 | 16.14 | 487,828 | 05:00:05 |
From Jul 2023 to Jul 2024
By Colin Kellaher
Day One Biopharmaceuticals has won U.S. Food and Drug Administration priority review for its application seeking approval of its lead product candidate tovorafenib in the most common brain tumor diagnosed in children.
The Brisbane, Calif., clinical-stage biopharmaceutical company on Monday said the application covers tovorafenib as a monotherapy in relapsed or progressive pediatric low-grade glioma.
The FDA grants priority review to medicines that have the potential to provide significant improvements in the treatment of a serious disease, and the designation shortens the review period.
Day One said the FDA set a target action date of April 30, 2024, adding that the agency isn't currently planning to hold an advisory committee meeting to discuss the application.
Write to Colin Kellaher at colin.kellaher@wsj.com
(END) Dow Jones Newswires
October 30, 2023 08:43 ET (12:43 GMT)
Copyright (c) 2023 Dow Jones & Company, Inc.
1 Year Day One Biopharmaceuticals Chart |
1 Month Day One Biopharmaceuticals Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
